6th In-House Impact: Biopharma Summit 2025

As the regulatory landscape continues to evolve, 2025 is a pivotal year for legal leaders in biopharma. The 6th In-House Impact: Biopharma Summit is your exclusive opportunity to unite with top legal minds from Takeda, Kura Oncology, Neurocrine Biosciences, and more to tackle today's most pressing challenges-tariffs, financing, M and A strategy, and beyond.

Speakers: Andrew Reardon, Chief Legal Officer, Ligand Pharmaceuticals, Benjamin Hsing, President, Asian American Bar Association of New York, Darin Lippoldt, Chief Legal Officer, Neurocrine Biosciences, Dario Scimeca, General Counsel, Precision BioSciences, Elbert Chiang, Vice President, Intellectual Property, Beam Therapeutics, Gregory Montalbano, Associate General Counsel and Head, Compliance, Assertio Therapeutics, Guled Adam, General Counsel, Sobi NA, James Singleton, General Counsel, Numab Therapeutics, Jenny Robertson, Chief Business and Legal Officer, Lexeo Therapeutics, Jessica Sergi, Associate General Counsel, EMD Serono, Joseph Barry, General Counse, Merz Pharmaceuticals, Kara DelTufo, Senior Director, Associate General Counsel, Foundation Medicine, Rupa Cornell, Vice President and Head Counsel for Vaccine Business Unit, Takeda Pharmaceutical, Shannon Moesaa, Senior Vice President, Legal, Ardelyx, Shawnte Mitchell, Chief Legal Officer; Corporate Secretary, Olema Oncology, Tamara Tompkins, Chief Legal Officer, Insitro, Teresa Bair, Chief Legal Officer, Kura Oncology